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It is well known that iodinated radiographic contrast media may cause kidney dysfunction, particularly in patients with preexisting
renal impairment associated with diabetes. This dysfunction, when severe, will cause acute renal failure (ARF). We may define
contrast-induced Acute Kidney Injury (AKI) as ARF occurring within 24–72 hrs after the intravascular injection of iodinated
radiographic contrast media that cannot be attributed to other causes. The mechanisms underlying contrast media nephrotoxicity
have not been fully elucidated and may be due to several factors, including renal ischaemia, particularly in the renal medulla,
the formation of reactive oxygen species (ROS), reduction of nitric oxide (NO) production, and tubular epithelial and vascular
endothelial injury. However, contrast-induced AKI can be prevented, but in order to do so, we need to know the risk factors. We
have reviewed the risk factors for contrast-induced AKI andmeasures for its prevention, providing a long list of references enabling
readers to deeply evaluate them both.
1. Introduction
It is well known that using iodinated radiographic contrast
media may cause kidney dysfunction, especially in patients
with preexisting renal impairment and in those with diabetes.
This dysfunction may range between a slight increase in
serum creatinine and severe acute renal failure with anuria
[1].
We may define Contrast-Induced Nephropathy (CIN)
or contrast-induced Acute Kidney Injury (AKI) as an acute
renal failure (ARF) occurring within 24–72 hrs after the
intravascular injection of iodinated radiographic contrast
media (used to improve the visibility of internal organs
and structures in X-ray based imaging techniques such as
radiography and computed tomography—CT) that cannot
be attributed to other causes. It is therefore an iatrogenic
disease which represents the third most common cause of
hospital-acquired ARF after surgery and severe hypotension.
It is usually a nonoliguric and asymptomatic transient decline
in renal function, which is mirrored by an increase of serum
creatinine (SCr) by 0.5mg/dL (or more) or by a 25% (or
more) increase in SCr from baseline [2, 3], peaking on the
third to fifth day, and returning to baseline within 10–14
days. Since fluctuations in SCr level may occur naturally
or in response to acute medical instability [4], it is better
to consider, instead of the increase of SCr, the decrease
of creatinine clearance (CrCl) calculated from SCr, age,
body weight, and gender using either the MDRD (Modi-
fication of Diet in Renal Disease) calculation [5] or CKD-
EPI (Chronic Kidney Disease Epidemiology Collaboration)
equation [6], or the simple Cockcroft-Gault formula: (140 −
number years of age) × kg body weight/72/mg/dL of SCr,
in females the result × 0.85 [7]. This is called the estimated
glomerular filtration rate (eGFR) that allows us to avoid the
measurement of CrCl, as derived from 24-hour urine col-
lection, which is a cumbersome, impractical, and inaccurate
test.
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In some cases, AKI may cause a severe ARF with oliguria
(<400mL/24 hrs), requiring dialysis. In these patients the
mortality is high.
The clinical feature and the management of contrast-
induced AKI are the same as those for ARF due to other
causes [1, 8, 9].
2. Incidence
AKI accounts for 12% of all cases of hospital-acquired ARF
[10]. It occurs in up to 5% of hospitalized patients who exhibit
normal renal function prior to introduction of contrast
medium [11].
For outpatients, the risk for AKIwhen eGFR >45mL/min
per 1.73m2 seems to be very low (about 2%) [12]. In a
prospective, observational study of outpatients with mild
baseline kidney disease who underwent contrast-enhanced
CT, Weisbord and Palevsky [13] observed the occurrence of
AKI in less than 1% of outpatients with GFR >45mL/min
per 1.73m2. Thus, AKI is uncommon in patients with normal
preexisting renal function; it occurs more frequently in
patients with renal impairment particularly if associated with
diabetic nephropathy [4].
Bruce et al. [14] carried out a retrospective study analyz-
ing 11,588 patients who underwent CT either without contrast
or with a low osmolar contrast medium (iohexol) or an
iso-osmolar contrast medium (iodixanol); they observed no
significant difference in the incidence of AKI between the
iso-osmolar contrast medium and the control groups for all
baseline SCr values; the incidence of AKI in the low osmolar
contrast medium group was similar to that of the control
group up to an SCr level of 1.8mg/dL; but values of SCr above
1.8mg/dL were associated with a higher incidence of AKI in
the low osmolar contrast medium group [14].
Mitchell et al. [15] sought to define prospectively the
incidence of AKI in an unselected, consecutive, heteroge-
neous population of outpatients who received low osmolar,
nonionic contrast (Iopamidol-370, Isovue-370) for a contrast-
enhanced CT study of any body region in the emergency
department of a large, academic, tertiary care center. The
incidence of AKI was 11% (70 out of 633) among the 633
patients enrolled; six of the 70 cases of AKI subsequently
developed severe renal failure, five of whom required dialysis
or died.
Davenport et al. [16] determined the effect of intravenous
(i.v.) low osmolality iodinated contrast material (LOCM) on
the development of AKI following CT in patients with stable
renal function, stratified by pre-tomography eGFR. It was a
retrospective study performed over a 10-year period in 20,242
adult inpatients (10,121 untreated and 10,121 treated with i.v.
iodinated contrast media) with sufficient SCr data. They
concluded that i.v. LOCM is a risk factor for nephrotoxicity in
patients with a stable eGFR <30mL/min/1.73m2; there was a
trend toward significance at eGFR of 30–44mL/min/1.73m2.
No nephrotoxicity was observed in patients with a pre-
tomography eGFR ≥45mL/min/1.73m2. Thus, according to
these authors, i.v. LOCM is a nephrotoxic risk factor, but
not in patients with a stable SCr level <1.5mg/dL or eGFR
≥45mL/min/1.73m2 [17].
In a recent retrospective study on 53,439 patients in
whom SCr was regularly checked, McDonald et al. [18]
determined the effect of i.v. iodinated contrast material
exposure to the incidence of AKI: the incidence of AKI was
not significantly different in contrast media group compared
to control group. In a systematic review and meta-analysis
of controlled studies by the same group examining the
incidence of AKI in patients exposed to i.v. contrast medium
compared with patients undergoing an imaging examination
without contrast medium (control group), the incidence of
AKI, dialysis, and death was similar between the contrast
medium group and control group.This pattern was observed
regardless of i.v. contrast medium type, diagnostic criteria
for AKI, or whether patients had diabetes mellitus or renal
insufficiency [19].
Rudnick and Feldman [20] have evaluated whether AKI
is causally related to mortality and to what extent could
mortality in patients undergoing contrast procedures be
reduced by preventingAKI. A review of observational studies
and clinical trials allowed the conclusion that the deaths
of some patients with AKI are complicated by factors that
cannot be directly related to the use of contrast media,
such as liver disease, sepsis, respiratory failure, and bleeding.
However, it is plausible thatAKI contributes to cardiovascular
causes of death in patients with AKI.
In a 3-year retrospective study in an intensive care unit
(ICU), in which 299 patients undergoing a contrast media-
enhanced CT scan in whom changes in SCr between baseline
and itsmaximumvalue over the 96 hours after contrastmedia
injection were recorded, the incidence of AKI was 14%. The
need for renal replacement therapy and ICU mortality were
significantly higher in cases of AKI [21].
According to Solomon [12] among all procedures utilizing
contrast media for diagnostic or therapeutic purposes, coro-
nary angiography and percutaneous coronary interventions
(PCI) are associated with the highest rates of AKI [3] mainly
related to the intra-arterial injection and to the high dosage
of the contrast necessary, and also to the type of patients who
have advanced age, one or more comorbid conditions, and
more advanced vascular disease, hypertension, and diabetes
[22].
Solomon et al. [23] have studied in 294 patients, with
follow-up of at least 1 year after contrast exposure, the
relationship of AKI to long-term adverse events, such
as death, stroke, myocardial infarction, end-stage kidney
disease, percutaneous coronary revascularization, coronary
artery bypass graft surgery, cardiac arrest, development of
congestive heart failure or pulmonary edema, and the need
for permanent pacing. The rate of long-term adverse events
was higher in individuals with AKI. A reduction in the inci-
dence of AKI and long-term adverse events was observed in
regression analyses to adjust for possible known confounders.
This supports the view that AKI is causally related to long-
term adverse events rates.
Permanent severe renal failure requiring dialysis occurs
in 10% of patients with preexisting renal failure who develop
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further reduction in renal function after coronary angiog-
raphy [24], or in <1% of all patients undergoing PCI using
contrast agents [25].
3. Pathogenesis
The mechanisms underlying contrast media nephrotoxicity
have not been fully elucidated and may be due to several
factors (Figure 1). When iodinated radiographic contrast
media are injected intravenously or intra-arterially, they pass
from the vascular compartment through capillaries into the
extracellular space. They are eliminated almost entirely by
glomerular filtration, concentrated in the renal tubular lumen
bywater tubular reabsorption, thereby visualizing the urinary
tract [1].
The i.v. injection of radiographic contrast medium causes
an initial increase in renal blood flow that is then followed by
a more prolonged decrease in blood flow and accompanied
by a decrease in glomerular filtration rate (GFR), while the
extrarenal vessels show transient vasoconstriction followed
by a decrease in vascular peripheral resistances. The result
will be a renal ischaemia, particularly in the medulla [26,
27]. Oxygen delivery to the outer renal medulla is poor
even under normal physiologic conditions because of the
distance of the outer renal medulla from the descending
vasa recta. Thus, the ischemia will be more severe in the
outer renalmedulla.Medullary ischemia ismademore severe
by an increase in oxygen consumption (due to increase in
tubular reabsorption), an increase of intratubular pressure
secondary to contrast-induced diuresis, increased urinary
viscosity, and tubular obstruction, all frequently associated
with dehydration and decrease in the effective intravascular
volume [10].
In vitro experiments on the effect of contrast media
on arteries obtained from different animal species showed
different responses with respect to contraction/dilatation
depending on the type of vessels and animal species; in these
studies the contrast medium was not applied intraluminally
[28].
However, in one study by Sendeski et al. [29], specimens
of outer medullary descending vasa recta were isolated
from rats and microperfused intraluminally with a buffered
solution containing iodixanol, with an iodine concentration
of 23mg per milliliter to simulate the usual dosage utilized in
examinations in humans. The purpose was to study whether
this contrast medium modifies outer medullary descending
vasa recta vasoreactivity and nitric oxide (NO) production.
The authors demonstrated that iodixanol directly constricts
the descending vasa recta (52% reduction of their luminal
diameter) by reducing NO and significantly increases the
vasoconstrictor response to angiotensin II, thereby causing
severe local hypoxia. The authors conclude that iodixanol
in doses typically used for coronary interventions constricts
medullary descending vasa recta, intensifies angiotensin II-
induced constriction, and reduces bioavailability of NO.
Hypoxia may lead to the formation of reactive oxygen
species (ROS) [30, 31]. Generated during contrast-induced
renal parenchymal hypoxia, ROSmay exert direct tubular and
vascular endothelial injury and might further intensify renal
parenchymal hypoxia by virtue of endothelial dysfunction
and dysregulation of tubular transport [32, 33]. The decrease
in NO is believed to be due to its reaction with ROS in
particular superoxide [28, 34]. This reaction may lead to
the formation of the more powerful oxidant peroxynitrite
[35] that may be more detrimental. Myers et al. [36] have
demonstrated, by in vivo experiments in rats, that the
decrease in cortical and medullary microvascular blood flow
induced by a contrast medium is partly accounted for by the
downregulation of endogenous renal cortical and medullary
NO synthesis. Sendeski et al. [29] have demonstrated that the
superoxide dismutase mimetic Tempol reduced iodixanol-
induced vasoconstriction, thereby supporting the role of ROS
generated during contrastmedia administration inmedullary
descending vasa recta vasoconstriction. More recently Pisani
et al. [37] have demonstrated that a recombinant manganese
superoxide dismutase administered in vivo to rats undergoing
diatrizoate treatmentwas able to reduce renal oxidative stress,
thereby preventing the reduction of GFR and the renal histo-
logic damage that follows contrast media administration.
The toxicity caused by specific properties of contrast
media, such as osmolality, viscosity, and ionic strength, can
be differentiated from the cytotoxicity common to all contrast
media in studies using cell culture, isolated blood vessels, and
isolated tubules; contrastmedia, in fact, possess a cytotoxicity
that is probably caused by iodine and leads to apoptosis and
cell death of both endothelial and tubular cells [28].
Thus, the decrease in NO in the vasa recta may not be
totally accounted for by increased ROS production, as dam-
age to endothelial cells (including apoptosis) may be another
important factor; the decreased NO production in descend-
ing vasa recta, in fact, is partly due to a loss of endothelial cell
viability caused by contrast media [28]. Endothelial damage,
including nuclear protrusion, cell shrinkage, fenestration of
the endothelial layer, and formation ofmicrovilli (“blebbing”)
on the cell membrane, and cellular apoptosis have been
observed by scanning electron microscopy [38]. Endothelial
damage may also release endothelin and hence lead to vaso-
constriction. Heyman et al. [39] have in fact demonstrated
that i.v. administration of contrast media in rats induced
an increase in plasma concentration of endothelin and that
contrast media stimulated endothelin release from cultured
bovine endothelial cells, suggesting a direct effect of ionic and
nonionic agents on vascular endothelium. Reduced levels of
prostaglandins have also been suggested to predispose to AKI
[40].
In addition to endothelial damage (the endothelial cells
are the first to come in contact with intravenously injected
contrast agents), contrastmedia cause damage also on epithe-
lial tubular cells [41]. In fact, the contrast media are filtered
by glomeruli and are concentrated inside the renal tubules,
exposing the renal tubular cells to even worse direct damage.
Direct tubular epithelial cell toxicity by contrast media has
been observed in studies of isolated tubule segments and
cultured cells substantiated by disruption of cell integrity
and apoptosis. The cell damage may be aggravated by factors
such as tissue hypoperfusion and hypoxia, by properties
of contrast media, such as ionic strength, high osmolarity,
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Figure 1: The complex mechanisms that lead to radiocontrast-associated decline of GFR. The dotted arrows indicate the reaction of the
reactive oxygen species (ROS) (superoxide anions: O
2
∙−) with nitric oxide (NO) that not only causes a reduction in NO levels but also leads
to the formation of peroxynitrite anion (ONOO−), a potent oxidant that causes cell injury.
and/or viscosity, and by clinically unfavourable conditions,
such as preexisting renal impairment particularly secondary
to diabetic nephropathy, salt depletion and dehydration,
congestive heart failure, and concurrent use of nephrotoxic
drugs [1, 28, 42, 43]. The biochemical changes underlying
the epithelial damage have been extended to study changes
in major intracellular signalling pathways involved in cell
survival, death, and inflammation [31, 44–51] in vitro in
cultured renal tubular cells [52]. Studies in animals and
in vitro studies suggest that iodinated contrast media can
directly induce caspase-mediated apoptosis of renal tubular
cells. It seems that contrast-induced apoptosis is due to the
activation of shock proteins and the concurrent inhibition of
cytoprotective enzymes and prostaglandins [53, 54].
4. Risk for Development of AKI
The identification of conditions that represent the risks for the
development of AKI is of major importance in the prevention
of AKI.
According to the European Society of Urogenital Radi-
ology the real risks for AKI are represented by preexisting
renal impairment, particularly when secondary to diabetic
nephropathy, by salt depletion anddehydration, by congestive
heart failure, by advanced age (>70 years), and by the
concurrent use of nephrotoxic drugs [2].
Hereafter we discuss the different risk factors.
4.1. Preexisting Impairment of Renal Function. The presence
of renal insufficiency, irrespective of its cause, represents
the main risk condition. The lower the eGFR is, the greater
the risk of AKI following the administration of contrast
media will be. According to Mehran and Nikolsky [3] an
eGFR of 60mL/min/1.73m2 is a reliable cutoff point for
identifying patients at high risk for the development of
AKI, the incidence of which, in patients with underlying
chronic renal failure (CRF), ranges from 14.8 to 55%. In a
recent retrospective observational in-hospital study in 1160
patients with or without chronic kidney disease (eGFR ≥
60mL/min/1.73m2), however, Neyra et al. [55] have observed
that AKI occurredwith similar frequency, following coronary
angiography, in both patients with and without chronic
kidney disease (eGFR ≥ 60mL/min/1.73m2).
4.2. Diabetes Mellitus. An important risk factor is diabetes
mellitus, particularlywhen associatedwith renal insufficiency
[56].
In a study by Manske et al. [57] 59 insulin-dependent
diabetics with a mean SCr level of 5.9mg/dL underwent
coronary angiography as part of a pretransplant evaluation;
24 azotemic diabetics undergoing inpatient evaluation not
including angiography for transplantation formed the control
group. Contrast-induced AKI (defined as an SCr increase of
greater than 25%whenmeasured 48 hours after radiocontrast
exposure) occurred in 50% of patients and none in controls.
The authors conclude that azotemic patients with diabetes are
at high risk of developing AKI (usually reversible but requir-
ing short-term dialysis in some patients) even when less than
100mLof radiocontrast agent are used; they suggest using less
than 30mL of radiocontrast agent to minimize renal damage.
According to Mehran and Nikolsky [3] at any given degree
of baseline GFR, diabetes doubles the risk of developing
AKI compared with nondiabetic patients [58]. The incidence
of AKI in diabetic patients varies from 5.7 to 29.4%. The
administration of iodinated radiocontrast media to diabetics
acutely reduces renal parenchymal oxygenation, a reduction
that is most prominent in the renal medulla, since it already
functions at low oxygen tension [58]. The biologically active
endothelins are produced by proteolysis of the precursor
preproendothelins under the action of endothelin-converting
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enzyme that plays a key role in increasing circulating and
renal endothelin levels found both in diabetes and after
exposure to contrast agents. This may explain the particular
susceptibility of diabetic patients to contrast media [58].
The increased incidence of AKI in diabetic patients has
also been attributed to hypersensitivity of renal vessels of
diabetics to adenosine, a vasoconstrictive agent, since exper-
imental studies have shown increased adenosine-induced
vasoconstriction in the kidneys of diabetic animals and the
administration of adenosine receptor antagonists reduces the
risk of development of contrast-induced AKI in both diabetic
and nondiabetic patients [59].
It has been demonstrated that, in patients with diabetes,
hypercholesterolemia is the strongest predictor of AKI [60].
Despite the evidence mentioned, most authors do not
regard the presence of diabetes mellitus in the absence of
renal failure as a risk factor for AKI [61]. In a prospective
observational study Morabito et al. [62] have evaluated the
incidence of contrast-induced AKI in all unselected patients
who underwent elective or emergency coronary angiography
or PCI in their department throughout a period of 11
months. They observed a 5.1% incidence of AKI. In diabetic
patients with preserved renal function and without other risk
factors, the rate of AKI was comparable to that of a nondi-
abetic population, while clinically important AKI occurred
in diabetic patients with underlying chronic renal disease
[1].
4.3. Concomitant Use of Other Drugs. Radiocontrast media
are medical drugs used for diagnostic purpose. The con-
comitant use of other drugs may represent a risk factor for
contrast-induced AKI. This is undoubtedly the case when
using nephrotoxic drugs, such as aminoglycosides (which
have a direct nephrotoxic effect), amphotericin (causes dis-
tal tubule dysfunction, impaired urine concentration and
potassium and magnesium wasting), cyclosporin A (a direct
cellular toxin which impairs lysosome function in both
proximal and distal tubules and evokes tubulo-interstitial
changes), cisplatin (attaches to sulphhydryl groups which are
essential for proper enzyme function) [63].
Also the concomitant use of nonsteroidal anti-
inflammatory drugs represents an important risk factor
because of their inhibition of the vasodilatory prostaglandins
biosynthesis. According toMorcos [64], in fact, the damaging
effect of contrast media on the kidney partly involves the
osmolality-dependent activation of the tubuloglomerular
feedback mechanism and the modulation of the intrarenal
production of vasoactive mediators such as prostaglandins,
NO, endothelin, and adenosine. Thus, reduction in the
synthesis of the endogenous vasodilator prostaglandins
(as occurring following the use of nonsteroidal anti-
inflammatory drugs) will increase the nephrotoxicity of
contrast media.
The concomitant use of angiotensin-converting enzyme
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)
may also represent a risk factor, at least according to some
authors. There are, however, conflicting opinions on this
point.
Some authors have described protective effects. Thus,
considering the possible role of medullary ischaemia medi-
ated by renin angiotensin system in genesis of contrast-
induced AKI, Gupta et al. [65] investigated the role of
the ACEI captopril in preventing AKI. The rationale was
that angiotensin II is a main effector peptide in the renin-
angiotensin system and plays a very important role in
controlling renal homeostasis as a vasoconstrictor. Thus,
captopril might prevent AKI by reducing the increase in
angiotensin II. Seventy-one patients with diabetes mellitus
undergoing coronary angiographywere included in the study.
Patients received captopril in a dose of 25mg thrice a day
for three days, starting one hour prior to angiography, while
the patients in the control group underwent angiography
without receiving captopril. AKI developed in 29% of the
control group; the administration of captopril reduced the
risk of development of contrast-induced AKI by 79%. The
authors concluded that captopril offers protection against
development of contrast-induced AKI.
Similarly, in an experimental study in Sprague-Dawley
rats, Duan et al. [66] administered telmisartan to confirm
its protective role against nephrotoxicity induced by contrast
media. Glycerin was given to all rats to induce renal injury.
Diatrizoate, a high-osmolar contrast medium (HOCM), or
iohexol, a low-osmolar contrast medium (LOCM) (10mL/kg
b.w., 300mg I/mL), was given through a caudal vein. In
diatrizoate-injected rats, SCr level was increased (𝑃 < 0.001).
Both HOCM (diatrizoate) and LOCM (iohexol) caused renal
tubular cell apoptosis in the kidneys damaged by glycerin.The
renal caspase-3 activity and angiotensin II levels in HOCM
and LOCM groups were higher than those in glycerol control
group (𝑃 < 0.001). The renal injury was also assessed
by histology. Telmisartan protected the renal tissue from
nephrotoxicity induced by contrast media.
In contrast, many have suggested that patients with
chronic renal disease under treatment with ACEIs or ARBs
are at higher risk for developing AKI particularly in the
elderly. Thus, Cirit et al. [67] have evaluated the influ-
ence of chronic ACEIs administration on the development
of contrast-induced AKI in patients undergoing coronary
angiography. The 230 patients with renal insufficiency and
age ≥65 years were divided into two groups: 109 users of
ACEI, ACE inhibitor group, 121 nonusers, control group:
AKI occurred in 17 patients (15.6%) of the ACEI group
and 7 patients (5.8%) of the control group (𝑃 = 0.015).
They conclude that chronic ACEI administration is a risk for
developing AKI in elderly patients with renal insufficiency.
Kiski et al. [68] have performed a prospective, single-
centre study to compare different treatments for AKI pre-
vention; 412 patients were included in the study, 269 (65.3%)
of whom were taking ACEI (𝑛 = 236) or ARBs (𝑛 = 33).
The occurrence of AKI within 72 h was significantly higher
in patients treated with ACEI or ARBs (11.9 versus 4.2%, 𝑃 =
0.006).
In a retrospective study of Rim et al. [69] among 11,447
patients receiving coronary angiography or PCI, 1,322 were
receiving either ACEI or ARBs. ACEI/ARBs users showed
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an increased incidence of contrast-induced AKI compared to
nonusers: 11.4% versus 6.3% (𝑃 < 0.001).
A single-center retrospective case-control study was con-
ducted by Umruddin et al. [70] on a total of 201 patients who
were exposed to nonionic radiocontrast agents for coronary
angiography, to evaluate the influence of ACEI and ARBs use
in the etiology of AKI. They identified patients who met the
criteria for AKI (a rise in SCr of more than 25% from the
baseline within 48 hours of radiocontrast agent exposure and
the absence of another cause) (AKI group); from the same list
they also identified an age-, sex-, and baseline SCr-matched
control group who did not meet the criteria for AKI (control
group). They found that 56 patients (58.3%) out of 96 of the
AKI group were on chronic ACEI or ARBs therapy, while
the control group had only 36 (34.3%) out of 105 patients
(𝑃 < 0.001). They concluded that the use of ACEI and ARBs
is an independent risk factor for developing AKI.
Some authors suggest discontinuing the use of ACEIs and
ARBs 48 hours prior to exposure to radiocontrast agents,
especially in patients with multiple risk factors [70, 71].
Others, however, believe that withholding ACEIs and
ARBs 24 h before coronary angiography does not influence
the incidence of AKI in stable patients with CRF. Thus,
Rosenstock et al. [72] undertook a randomized trial to
evaluate the effect of withdrawing ACEIs or ARBs 24 h prior
to coronary angiography on the incidence of AKI associated
with coronary angiography.The 220 patients with CRF, stages
3-4 (eGFR 15–60mL/min/1.73m2), on ACEI or ARB therapy
were randomized before angiography to either ACEI/ARB
continuation group or discontinuation group. There was no
statistically significant difference in the incidence of AKI.The
authors concluded that withholding ACEIs and ARBs 24 h
before coronary angiography does not appear to influence
the incidence of AKI in stable patients with CRF stages
3-4.
4.4. Reduction of Effective Circulating Blood Volume. Dehy-
dration and salt depletion secondary to abnormal fluid losses
(gastrointestinal, renal, or dermal losses) associated with
insufficient salt intake represent a predisposing condition to
AKI by radiographic contrast media, as it is predisposing
to any form of ARF [73]. But the reduction of “effective”
circulating blood volume is also a risk factor to any form of
ARF [8] and in particular to AKI by contrast media.
The “effective” circulating blood volume may be defined
as the relative fullness of the arterial tree as determined
by cardiac output, peripheral vascular resistance, and total
blood volume; it is usually reduced in congestive heart failure
(because of reduced cardiac output), in cirrhosis with ascites
(because of reduced peripheral resistance), and in nephrotic
syndrome (because of reduced blood volume secondary to
protein losses) [8].
A reduction of “effective” circulating blood volume may
be due to congestive heart failure, compromised left ven-
tricle systolic performance, prolonged hypotension, or liver
cirrhosis or nephritic syndrome. Under such circumstances
renal vasoconstriction induced by adenosine is accentuated
thereby making renal ischemia more severe.
4.5. Multiple Myeloma. Multiple myeloma is a malignancy
with clinical severity and variable survival time. AKI by con-
trastmedia was described for the first time in 1954 in a patient
with multiple myeloma receiving intravenous pyelography
[74]. Many radiologists have withheld contrast agents from
all patients with myeloma, afraid to induce AKI following
iodinated radiographic contrast medium use. Early articles,
in fact, linked the intravenous administration of contrast
agents with the development of renal failure in patients with
multiple myeloma, leading to the conclusion that iodinated
radiographic contrast media are contraindicated in patients
with myeloma [75–79].
In a recent retrospective clinical study Pahade et al. [80]
examined the risk of AKI in patients with multiple myeloma
following nonionic iodinated contrastmedia injection during
CT. Their retrospective review of medical records identified
patients with a diagnosis of myeloma who underwent a
contrast-enhanced CT examination of the chest, abdomen,
or pelvis. Their search yielded a total of 56 eligible myeloma
patients (24 women and 32 men) who underwent a total
of 103 CT examinations; the average age was 65 years
(range 37–93 years). AKI was defined by an increase in SCr,
after the examination, of 25% or more, or of 0.5mg/dL or
more, compared with its level before the examination, both
within 48 hours and within 7 days of contrast-enhanced CT.
The results showed a 5% incidence of AKI using the 48-
hour definition. On the basis of their results, the authors
concluded that the incidence of AKI following contrastmedia
administration in patients with multiple myeloma with a
normal SCr is low and correlates with 𝛽
2
-microglobulin
levels; thus, the administration of contrast agents in these
patients is relatively safe.The serum level of𝛽
2
-microglobulin
increases with higher tumor burden and with diminished
renal function. In their study the mean 𝛽
2
-microglobulin
level has shown a statistically significant association with
the development of AKI. According to the authors, a review
of 𝛽
2
-microglobulin serum levels may be beneficial before
administering the contrast agent to patients with myeloma,
because it likely serves as a marker of patients who are at a
higher risk of developing AKI. They suggested a threshold
value of less than 2.8mg/L of 𝛽
2
-microglobulin serum level
for essentially eliminating the risk of AKI [80].
The assessment of Bence Jones proteinuria is unnecessary
for evaluating the risk of kidney failure in patients with
multiple myeloma, since this test cannot be considered a
surrogate biomarker of kidney function [81].
Wemay conclude that multiple myeloma per se cannot be
considered a main risk factor for developing AKI following
intravascular administration of iodinated contrast media.
The risk, however, becomes important when associated with
comorbidities such as CRF, diabetes, hypercalcemia, dehy-
dration, and use of nephrotoxic drugs [81].
4.6. Osmolality and Viscosity of Contrast Media. Osmolality
of contrast media compared with the osmolality of plasma
seems to play an important role in nephrotoxicity. Contrast
media usually have high viscosity and greater osmolality
(moremolecules per kilogram of water) than plasma. Ionicity
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is the characteristic of a molecule to break up into a cation
and an anion, resulting in more molecules per kilogram of
water and thus increasing osmolality. Nonionic agents not
having this property are less osmolar. The osmotoxic effect
of contrast agents is described in terms of the ratio of iodine
atoms to dissolved particles: the higher the ratio, the better
the attenuation of X rays [10, 82].
Ionic high-osmolar contrast media (HOCM, e.g., diatri-
zoate, 1500 to 1800mOsm/kg, i.e., 5–8 times the osmolality of
plasma) have a ratio of 1.5 : 1, nonionic low-osmolar contrast
media (LOCM, e.g., iohexol, 600 to 850mOsm/kg, i.e., 2-
3 times the osmolality of plasma) have a ratio of 3 : 1, and
nonionic iso-osmolar contrast media (IOCM, e.g., iodixanol,
approximately 290mOsm/kg, i.e., same osmolality as plasma)
have a ratio of 6 : 1 [83].
Adverse reactions to contrast media range from 5% to
12% for HOCM and from 1% to 3% for LOCM. It has
been shown that LOCM rather than HOCM are beneficial
in the prevention of contrast-induced AKI to patients with
preexisting renal failure [82, 84–86]. Iodixanol (IOCM)
seems less nephrotoxic than iohexol (LOCM) [82, 87], at
least in patients with intra-arterial administration of the drug
and renal insufficiency [88, 89]. But recent studies and meta-
analyses have found no significant difference in the rates of
AKI between IOCM and LOCM [88–93].
In addition to the osmolality of iodinated contrast media,
their viscosity is very important, indeed; while the osmolality
of a given contrast medium solution, in fact, increases only
linearly with the molar concentration, the viscosity increases
exponentially [94]. Thus, the low osmolality achieved with
the IOCM came at the price of considerably increased vis-
cosity; at comparable iodine concentration and X-ray attenu-
ation nonionic dimer IOCM have about twice the viscosity
of nonionic monomer LOCM [95]. The higher viscosity of
nonionic dimer IOCM probably relies on a number of the
compounds’ features including the molecules’ shape and the
flexibility of the bridge between the two benzene nuclei [96].
Most of the water filtered by the glomerulus is reabsorbed
along the length of the renal tubule, thereby causing con-
siderable concentration of the contrast medium within the
tubule itself. This results in a progressive increase in tubular
fluid osmolality and, due to the exponential concentration-
viscosity relationship, an overproportional increase in tubular
fluid viscosity as well as in the urine viscosity [94].
Since the fluid flow rate through a tube increases with the
pressure gradient and decreases with the flow resistance and
since the resistance increases proportionally to fluid viscosity,
the increased viscosity caused by a contrastmedium increases
the intratubular pressure [97]. This causes a decrease in
glomerular filtration and contributes to renal medullary
hypoperfusion and hypoxia since circular distension of the
tubules results in compression of medullary vessels such as
the vasa recta [94]. On the other hand, the increased flow
resistancemarkedly slows down the tubular flow rate, thereby
increasing the contact time of cytotoxic contrast medium
with tubular epithelial cells and consequently increasing their
damaging effect.
In case of dehydration angiotensin II and vasopressin
augment tubular fluid reabsorption, which further increases
the tubular concentration of the contrast medium, and,
due to the concentration-viscosity relationship, overpro-
portionally increases tubular fluid and urine viscosity.
Accordingly, dehydration and/or volume contraction are
major individual risk factors for contrast-induced AKI [94].
Hence, the strong recommendation for hydration of the
patients before the exposure to contrast media, particularly
in the elderly due to an impaired sensation of thirst
[98].
In vivo studies that directly compared urine viscosities
following LOCM versus IOCM administration in dogs and
rats demonstrated a larger increase in urine viscosity follow-
ing IOCM [94, 99–102]. The LOCM causes an increase of
tubular fluid viscosity; but the viscosity increase by IOCM is
several times larger; the higher the viscosity and the lower the
osmolality, the longer the cells exposed to contrast media and
the more they are injured [94].
Micropuncture studies in rats found that the IOCM,
iotrolan, increased tubular pressure and decreased single
nephron GFR much more than HOCM and LOCM did [97,
103].
4.7. Use of Large Doses or Multiple Injections of Iodinated
Contrast Media. The risk of contrast-induced AKI is dose-
dependent; it increases with the volume of contrast medium
administered during the procedure and with their multiple
injections within 72 hours [104–106]. Larger volumes of
contrast agents are used in coronary angiography than in
other imaging studies. Therefore, patients who undergo
coronary angiography (these patients usually have one or
more comorbid conditions) have AKI more frequently than
other patients [107, 108].
4.8. Route of Administration of Iodinated Contrast Media.
Many studies have demonstrated that i.v. contrast media
are less risky than intra-arterial contrast media [109–111].
Iodinated radiographic contrast media are more nephrotoxic
when given intra-arterially because of the higher acute
intrarenal concentration [10, 88], particularly if the arterial
injection is suprarenal [112]. It has been demonstrated that,
while performing aortography, the closer to the renal arteries
the injection of contrast medium occurs, the higher the risk
of AKI will be [104].
Dong et al. [88] have performed a study to examine
the association between administration route and relative
renal safety of iodinated radiographic contrast agents. They
searched all published articles indexed in Embase, Medline,
and the Cochrane Central Register of Controlled Trials, in
the period 1980–2010 and found 11 randomized controlled
trials including 2,210 patients with intra-arterial route and
7 including 919 patients with intravenous route of admin-
istration. The meta-analysis suggested that administration
route may affect the renal safety of different contrast agents.
Their results showed that compared with a pool of LOCM,
iodixanol (IOCM) was associated with less risk of contrast-
induced AKI when administered intra-arterially rather than
intravenously.
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4.9. Advance Age. Advance age, that is, >65 years, represents
a predisposing factor to contrast-induced AKI. The reasons
for higher AKI risk in the elderly aremultifactorial, including
age-related changes in renal function (which favours renal
sodium and water wasting) [98], the presence of old vessels,
of one or more comorbid conditions, such as dehydration,
due to impaired sensation of thirst in old subjects, or chronic
renal disease particularly if under treatment with ACEIs or
ARBs, and the presence of more advanced vascular disease,
of coronary artery disease, of longstanding hypertension, and
of diabetes.
4.10. The Presence of Anemia. Anemia is a risk factor for
AKI by contributing to renal ischemia. Nikolsky et al. [113]
have studied the relationship between hematocrit and the
occurrence of AKI. Of 6,773 consecutive patients treated
with PCI, contrast-induced AKI (an increase of ≥25% or
≥0.5mg/dL in preprocedure SCr, at 48 hours after procedure)
occurred in 942 (13.9%) patients. The rates of AKI were the
highest (28.8%) in patients who had the lowest level for both
baseline eGFR and hematocrit; patients with the lowest eGFR
but relatively high baseline hematocrit values had remarkably
lower rates of AKI. The authors conclude that correcting the
hematocrit before PCI might decrease the rates of contrast-
induced AKI.
4.11. Sepsis. Sepsis is a risk factor, probably because of
direct tubular damage by bacterial toxins and impairment of
circulation [63].
4.12. The Presence of Transplanted Kidney. Patients with
renal transplantation are at a higher risk of contrast-induced
AKI due to concomitant use of nephrotoxic drugs, such as
cyclosporine, and higher prevalence of diabetes and renal
insufficiency. Ahuja et al. [114] have evaluated the safety of
iodinated radiographic contrast injections in renal allograft
recipients. In a retrospective study they identified 44 patients
with functioning renal allograft who underwent different i.v.
or intra-arterial contrast studies. Renal function tests were
done before and after the contrast study in 35 of these patients,
who underwent coronary angiogram in 6 patients, CT scan
with intravenous contrast in 11, angiogram for evaluation of
peripheral vascular disease in 11, allograft angiogram with
angioplasty in 5, pulmonary angiogram in 1, and intravenous
pyelogram in 1 patient. The incidence of AKI (≥25% increase
in baseline SCr) in the renal allograft recipients was 21.2%
(7 of 33 patients). The incidence of AKI was lower 15.3% (4
of 26) in patients who received i.v. hydration compared to
42.8% (3 of 7) in patients who received no prophylaxis prior
to radiographic contrast agents.
5. Prevention of AKI
It is absolutely necessary to try to prevent contrast-induced
AKI. This is even more necessary in high risk patients. The
following are useful suggestions for its prevention.
5.1. Monitoring Renal Function. Renal function should be
monitored in any patient before any radiographic procedure
that requires the use of radiographic iodinated contrast
agents. SCr should be checked before and after the use
of contrast medium. In patients at high risk of AKI, SCr
should be checked before and once daily for 5 days after
the radiographic procedure [1]. The increase in SCr after the
contrast agent administration will indicate nephrotoxicity.
5.2. Removal of Nephrotoxic Drugs. Potentially nephrotoxic
drugs should be discontinued, whenever possible, before the
contrast procedure. This is the case with aminoglycosides,
whose direct nephrotoxic effect would potentiate the contrast
nephrotoxicity, vancomycin, amphotericin B, cisplatin, and
nonsteroidal anti-inflammatory drugs.
In those cases in which aminoglycosides cannot be
removed, its dosage should be reduced. Thus, the European
Renal Best Practice (ERBP) [115] suggests, for the treatment
of infections in patients with normal kidney function in
steady state, to administer aminoglycosides as a single dose
daily rather than multiple doses, but with monitoring of
aminoglycoside blood levels. For amphotericin B, the ERBP
recommends that saline loading be implemented in all
patients receiving any formulation of amphotericin B [115].
Metformin is a biguanide (dimethylbiguanide) that is
used in patients with non-insulin-dependent diabetes mel-
litus (type II diabetes) as an oral antihyperglycemic med-
ication. Since it stimulates intestinal production of lactic
acid, potential harm may happen when renal failure occurs.
Approximately 90% of metformin is eliminated via the kid-
neys in 24 hrs. Thus, renal insufficiency (GFR < 70mL/min)
will lead to its retention in the tissues and to lactic acidosis
that can be fatal, since the onset of renal injury after the
administration of contrast medium is quite rapid. Thus, the
drug has to be discontinued at least 12 hours before the
contrast and not be resumed for a minimum of 36 hours
after the procedure, or longer if the SCr has not returned to
baseline [116].
We have already discussed the controversial opinions
on the role of ACEIs and ARBs as potential risk factors
for contrast-induced AKI. According to KDIGO guidelines
for Acute Kidney Injury Work Group, there is insufficient
evidence to recommenddiscontinuation of thesemedications
prior to contrast administration [117].
5.3. The Choice of the Radiographic Contrast Agent. It is
very important to choose the least nephrotoxic radiocontrast
agent. The LOCM (e.g., iohexol) are less nephrotoxic than
HOCM (e.g., diatrizoate). Furthermore, the IOCM (e.g.,
iodixanol) seem to be less nephrotoxic than the LOCM [1, 10].
A multicenter, randomized, double-blind comparison
of iopamidol (LOCM) and iodixanol (IOCM) has been
performed by Solomon et al. [91] in patients with chronic
kidney disease. The incidence of contrast-induced AKI was
not statistically different after the intra-arterial administra-
tion of iopamidol or iodixanol to high-risk patients, with
or without diabetes mellitus. The authors conclude that
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iodixanol (IOCM) and iopamidol (LOCM) are iodinated
contrast agents of choice to reduce risk of AKI.
5.4. The Dosage of the Radiographic Contrast Agent. The
lowest dosage possible of the radiographic contrast agent
should be used.
High doses of contrast agents are required in PCI. For this
procedure, some formulas have been suggested to calculate
the dosage that is least dangerous for renal function [1].
(1) Cigarroa’s formula: 5mL of contrast per kg b.w./SCr
(mg/dL) with maximum acceptable dose of 300mL
for diagnostic coronary arteriography [118].
(2) Laskey’s formula: volume of contrast to calculated
creatinine clearance ratio with a cut-off point of the
ratio at 3.7 for PCI; a ratio >3.7 would be associated,
following contrast use, with a decrease in CrCl [119].
Recently Gurm et al. [120] have suggested a cut-
off point at 2.0: below a ratio of 2.0 AKI would be
a rare complication of PCI, but it would increase
dramatically at a ratio of 3.0.
(3) A new formula seems to be superior and consists of a
ratio of grams of iodine to the eGFR; a ratio of 1.42,
or even better a ratio of 1.0, would prevent contrast-
induced AKI [121].
5.5. Adequate Hydration. The crucial preventive measure of
contrast-induced AKI is an adequate hydration of the patient
[122, 123]. We must abolish the old suggestion to avoid any
oral intake starting the day before contrast administration,
a measure decided to prevent vomiting and nausea, that
was common with high-osmolality contrast agents, and to
allow for tracheal intubation in case of any emergency.
Undoubtedly the strategy to keep the patient in a fasting
state was correct; but many patients and physicians erro-
neously considered a restriction in fluids in parallel with the
restriction in food [122]. This misconception caused patient
dehydration before using iodinated contrast media.
Volume supplementation is the cornerstone for the pre-
vention of contrast-induced AKI. According to Mueller [122]
an oral or intravenous volume supplementation effectively
prevents AKI in low- and moderate-risk patients: 500mL of
water or soft drinks (e.g., tea) orally before and 2,500mL
for 24 hours after contrast administration in order to secure
urine output of at least 1mL/min in a non-dehydrated patient;
or i.v. injection of 100mL/hr of 0.9% saline solution starting
4 hrs before contrast administration and continuing for 24 hrs
afterward [124].
High infusion rate or high total fluid volume may result
in volume overload and trigger pulmonary edema in patients
with predisposing cardiac conditions. In these patients a
rather low infusion rate of 1mL/kg per hour has in general
been recommended and used in clinical practice [125]. In
high-risk patients adequate hydration may be obtained by i.v.
infusion of 0.9% saline at a rate of approximately 1mL/kg
b.w.per hour, beginning 6–12 hours before the procedure
and continuing for up to 12–24 hours after the radiographic
examination; this may be done only if urine output is
appropriate and cardiovascular condition allows it [122].
The rationale for volume supplementation is that hydra-
tion causes expansion of intravascular volume, suppression
of renin-angiotensin cascade, and consequent reduction of
renal vasoconstriction and hypoperfusion. The resulting
increase of diuresiswill decrease the concentration of contrast
material within the tubule lumen and its contact time, thereby
diminishing its direct toxicity on tubular epithelium; a higher
urine output is associated with a lower incidence of contrast-
induced AKI [125].
Some clinical studies and meta-analyses have shown that
sodium bicarbonate hydration is superior to sodium chloride
[126–132] at least when using LOCM [133].
Thus, Merten et al. [126] treated 119 patients with pre-
existing renal insufficiency, scheduled mainly for cardiac
catheterization, to receive either 154mEq/l sodium bicar-
bonate or equimolar sodium chloride, both given as an i.v.
bolus (3mL/kg per hour for 1 hour) immediately before the
administration of iopamidol, followed by an infusion at a
rate of 1mL/kg per hour for 6 hours after the procedure. The
incidence of AKI (defined as an increase of ≥25% of baseline
SCr within 2 days) was lower in the bicarbonate group: 1.7%
versus 13.6% (𝑃 = 0.02). Similarly Masuda et al. [127],
using the same protocol of bicarbonate infusion (number:
30) versus saline (number: 29) in 59 patients undergoing an
emergency coronary angiography or intervention, found an
incidence of AKI of 7% versus 35% (𝑃 = 0.01).
In a systematic review and meta-analysis using the
MEDLINE database, Navaneethan et al. [129] compared the
hydration with i.v. sodium bicarbonate with or without N-
acetylcysteine versus hydration with normal saline with or
without N-acetylcysteine. Sodium bicarbonate significantly
decreased the incidence of contrast-induced AKI.
The rationale for using bicarbonate infusion is explained
by the fact that any condition (such as acetazolamide admin-
istration or sodium bicarbonate infusion) that increases
bicarbonate excretion decreases the acidification of urine
and medulla. Consequently, this will reduce the production
(namely, inhibition of the generation of hydroxyl radicals
from H
2
O
2
) and increase the neutralization of oxygen free
radicals, thereby protecting the kidney from injury by con-
trast agents [128, 129, 134].
Other investigators did not find a benefit with sodium
bicarbonate hydration versus sodium chloride. Thus, in a
study of Brar et al. [135]Medline, EMBASE, Cochrane library,
and the Internet were searched for randomized controlled
trials comparing hydration between sodium bicarbonate
and chloride for the prevention of contrast-induced AKI
between 1966 and November 2008. A significant clinical
and statistical heterogeneity was observed that was largely
explained by trial size. Among the large randomized trials
there was no evidence of benefit for hydration with sodium
bicarbonate versus sodium chloride (10.7 and 12.5%, resp.) for
the prevention of AKI. The authors believe that the benefit
of sodium bicarbonate was limited to small trials of lower
methodological quality.
Shavit et al. [136] conducted a prospective, single-center
trial in 93 patients with CRF, stages III-IV, undergoing
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cardiac catheterization who received either an infusion of
0.9% sodium chloride and oral N-acetylcysteine (number:
42) or 154mEq/L sodium bicarbonate (number: 51). They
concluded that hydration with sodium bicarbonate is not
more effective than hydration with sodium chloride and oral
N-acetylcysteine for the prevention of contrast-induced AKI.
Vasheghani-Farahani et al. [137] prospectively enrolled,
in a single-center, double-blind, randomized, controlled trial
from August 2007 to July 2008, 72 patients undergoing
elective coronary angiography with an SCr level ≥1.5mg/dL,
uncontrolled hypertension, compensated severe heart failure,
or a history of pulmonary edema; the patients were assigned
to either an infusion of sodium bicarbonate plus half saline
(𝑛 = 36) or half saline alone (𝑛 = 36). The combination
therapy of sodium bicarbonate plus half saline did not offer
additional benefits over hydration with half saline alone in
the prevention of AKI.
Also an increased incidence of AKI with the use of i.v.
sodium bicarbonate has been reported. Thus, From et al.
[138] performed a retrospective study at the Mayo Clinic
in Rochester, Minnesota (USA), to assess the incidence of
contrast-induced AKI with the use of sodium bicarbonate
and N-acetylcysteine. A total of 11,516 contrast exposures
in 7977 patients had SCr values available for review before
and after iodinated contrast exposure. The use of i.v. sodium
bicarbonate was associated with increased incidence of
contrast-induced AKI compared with no treatment.
The ERBP [115] “recommends volume expansion with
either isotonic sodium chloride or sodium bicarbonate
solutions, rather than no volume expansion, in patients at
increased risk for AKI.”
5.6. Antioxidants. As mentioned, ROS have been proven
to play an important role in the renal damage caused by
iodinated radiocontrast agents. Hence, it is reasonable to
use antioxidants for preventing AKI. Lee et al. [139] treated
human embryonic kidney cells with three different contrast
media: ionic HOCM ioxitalamate, nonionic LOCM iopro-
mide, and IOCM iodixanol. All three contrast media caused
a significant reduction of cell viability at 24 hours (𝑃 <
0.001). Short-duration pretreatment with N-acetylcysteine
significantly improved cell viability compared with no N-
acetylcysteine pretreatment (𝑃 < 0.001).
Clinical studies have suggested a protective effect of ROS
scavenging with the administration of N-acetylcysteine [32,
140].
Tepel et al. [141] prospectively studied 83 patients with
CRF (mean SCr of 2.4mg/dL) planned to undergo CT with
a nonionic, low-osmolality contrast agent; the 83 patients
randomly received either N-acetylcysteine (600mg orally
twice daily) plus i.v. Infusion of 0.45% saline, both before and
after the contrast agent (n. 41), or placebo and 0.45% saline
(n. 42). An increase of at least 0.5mg/dL of SCr 48 hours
after administration of the contrast agent occurred in 1 out
of 41 patients in the N-acetylcysteine group (2%) and 9 out
of 42 patients in the control group (21%; 𝑃 = 0.01). The
authors concluded that N-acetylcysteine, given orally along
with hydration, prevents AKI by contrast agents in patients
with CRF.
Baker et al. [142] prospectively randomized 80 patients
with stable renal dysfunction, planned for cardiac catheter-
ization or intervention, to i.v. infusion of N-acetylcysteine
(150mg/kg in 500mL normal saline, 𝑛 = 41) or i.v. hydration
alone (𝑛 = 39). AKI occurred in 2 out of 41 patients in the
N-acetylcysteine group (5%) and in 8 out of 39 patients in the
hydration group (21%;𝑃 = 0.045)The authors concluded that
i.v. N-acetylcysteine has a protective effect against AKI.
Briguori et al. [143] tested whether a double dose of N-
acetylcysteine given orally could be more effective to pre-
vent contrast-induced AKI. They performed a prospective,
randomized study on 224 consecutive patients with SCr
≥1.5mg/dL and/or CrCl <60mL/min, referred to their insti-
tution for coronary and/or peripheral procedures. Patients
were randomly assigned to receive either 0.45% saline intra-
venously plusN-acetylcysteine at the standard dose of 600mg
orally twice daily (𝑛 = 110) or a double dose (1200mg orally
twice daily; 𝑛 = 114) before and after nonionic, LOCM
iobitridol (Xenetin-350) administration. An increase of at
least 0.5mg/dL of SCr 48 h after the procedure occurred in
12 out of 109 patients (11%) in the standard dose group and
in 4 out of 114 patients (3.5%) in the double dose group
(𝑃 = 0.038). In the subgroup with high contrast dose
(≥140mL), the AKI was significantly more frequent in the
standard dose group.The authors concluded that double dose
of oral N-acetylcysteine is more effective than standard dose
in preventing contrast-induced AKI, particularly when high
volumes of nonionic, low-osmolality contrast agent are used.
Some authors [144] demonstrated that high dose of oral
N-acetylcysteine (1,200mg twice a day before and on the
day of the procedure) is more beneficial than ascorbic acid
in preventing contrast-induced AKI in patients, especially
in diabetic patients, with renal insufficiency undergoing
coronary angiography.
Other authors did not find any significant protection
by N-acetylcysteine against radiographic contrast media
nephrotoxicity. Thus, Durham et al. [145] evaluated the
efficacy of N-acetylcysteine for the prevention of contrast-
induced AKI (defined as an increase of SCr by ≥0.5mg/dL)
in the setting of cardiac angiography: 79 patients with SCr
>1.7mg/dL were randomized to one of two groups: Group
1, i.v. hydration and N-acetylcysteine, 1200mg 1 hour before
and a second dose 3 hours after angiography; Group 2, i.v.
hydration and placebo. AKI developed in 24.0% of subjects,
26.3% in the N-acetylcysteine, and 22.0% in the placebo (P
= NS). The authors concluded that N-acetylcysteine is not
effective for the prevention of AKI after cardiac angiography.
Similarly in the retrospective study of From et al. [138] at
the Mayo Clinic, N-acetylcysteine alone and in combination
with sodium bicarbonate was not associated with any signif-
icant difference in the incidence of contrast-induced AKI.
Allaqaband et al. [146] prospectively compared the effi-
cacy of N-acetylcysteine, fenoldopam, and saline in prevent-
ing contrast-induced AKI in 123 high-risk patients with SCr
≥1.6mg/dL or CrCl of <60mL/min undergoing cardiovas-
cular procedures. The patients received either saline (0.45%
normal saline at 1mL/kg) for 12 hours before and 12 hours
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after the procedure, or fenoldopam (0.1 microg/kg/min) plus
saline for 4 hours prior and 4 hours after the procedure, or
N-acetylcysteine orally (600mg) plus saline every 12 hrs for
24 hours prior and 24 hours after the procedure. The authors
concluded that, in patients with CRF, N-acetylcysteine or
fenoldopamoffered no additional benefit over hydrationwith
saline in preventing AKI.
Goldenberg et al. [147] prospectively studied 80 patients
with SCr of 2.0mg/dL undergoing coronary angiogra-
phy: patients were randomly assigned to receive either N-
acetylcysteine (600mg orally t.i.d.) or placebo, in addition
to i.v. 0.45% saline (1mL/kg/hr), 12 hrs prior to and after
coronary angiography. There was no significant difference
in the increase of SCr ≥0.5mg/dL 48 hrs after coronary
angiography between the N-acetylcysteine group and the
placebo group (5% versus 8%, 𝑃 = 0.52).
Similarly Coyle et al. [148] did not find any benefit
by including N-acetylcysteine to the hydration regimen in
patients with diabetes mellitus in preventing AKI.
Similar results have been obtained by Ferrario et al.
[149] in their study in 200 elective, consecutive patients with
basal CrCl≤55mL/min receiving either oral N-acetylcysteine
(600mg bid the day before and the day of the exposure to
nonionic isosmolar contrast medium, Iodixanol, Visipaque,
plus saline i.v. 0.9% 1mL/kg/h 12–24 h before and 24 h after
the procedure, 𝑛 = 99) or placebo and saline at the same time
intervals (𝑛 = 101). Contrast-induced AKI was 8/99 (8.1%) in
the N-acetylcysteine group versus 6/101 (5.9%) in the placebo
group (𝑃 = 0.6).
Pannu et al. [150] performed a systematic review and
meta-analysis (15 studieswith a total of 1776 patients) to assess
the efficacy of N-acetylcysteine for preventing AKI after
administration of i.v. contrast media. The authors concluded
that N-acetylcysteine may reduce the incidence of acute
increase of SCr after i.v. contrast administration, but this
findingwas of borderline statistical significance; furthermore,
there was heterogeneity between trials.
Finally Gurm et al. [151] assessed the protective effect of
N-acetylcysteine against AKI in consecutive patients under-
going nonemergent PCI from 2006 to 2009 in the Blue
Cross Blue Shield of Michigan Cardiovascular Consortium.
Of the 90,578 PCIN-acetylcysteine was used in 10,574 (11.6%)
procedures. No differences in outcomes between patients
treated with N-acetylcysteine and those not receiving N-
acetylcysteine were observed for AKI (5.5% versus 5.5%, 𝑃 =
0.99) or death (0.6% versus 0.8%, 𝑃 = 0.15).
Despite these controversial results, it has been suggested
to use N-acetylcysteine in high-risk patients either with an
oral dose of 600mg twice daily the day before and the day
of procedure or, in patients unable to take the drug orally,
with an i.v. dose of 150mg/kg over half an hour before the
procedure or 50mg/kg administered over 4 hours [142].
Other antioxidants have been suggested to use against
contrast-induced AKI: vitamin C (ascorbic acid), vitamin E
(𝛼- or 𝛾-tocopherol), and Mesna.
Conflicting results have been obtained with the use of
ascorbic acid.
Thus, some authors have demonstrated that prophylactic
oral administration of ascorbic acid may protect against
contrast-induced AKI [152–154].
Spargias et al. [152] conducted a randomized, double-
blind, placebo-controlled trial of ascorbic acid in 231 patients
with an SCr ≥1.2mg/dL undergoing coronary angiography
and/or intervention. Contrast-induced AKI occurred in 11
out of 118 patients (9%) in the ascorbic acid group and in 23
out of 113 patients (20%) in the placebo group (𝑃 = 0.02)
thereby demonstrating a protective effect of ascorbic acid.
Alexopoulos et al. [153] examined the preventive effect of
ascorbic acid on the incidence of contrast-inducedAKI in 222
patients undergoing a coronary procedure. For patients who
used iodixanol, the incidence of AKIwas 7.4% for the ascorbic
acid patients and 21.6% for placebo patients (𝑃 = 0.02).
Finally Sadat et al. [154] performed a systematic review
with meta-analysis of randomized controlled trials (9 trials
in 1,536 patients) comparing the use of ascorbic acid with
placebo for the treatment of contrast-inducedAKI in patients
undergoing coronary angiography: patients receiving ascor-
bic acid had 33% less risk of AKI compared with patients
receiving placebo (𝑃 = 0.034).
Other authors demonstrated a nonprotective effect of
ascorbic acid against iodinated radiographic contrast media
nephrotoxicity [155].
Thus, Boscheri et al. [155] have carried out a randomized,
double-blind, prospective, and single center-study, evaluating
143 consecutive patients who received 1 g ascorbic acid or
placebo plus saline hydration prior to and after angiography:
no significant difference was detected in the incidence of AKI
between Vitamin C patients (5/74, i.e., 6.8%) and placebo
patients (3/69, i.e., 4.3%).
Tasanarong et al. [156] carried out a prospective, double-
blind, randomized, and placebo-controlled trial in 305
patients with CRF undergoing coronary procedures with
iopromide (LOCM). The oral administration of either
350mg/day of 𝛼-tocopherol or 300mg/day of 𝛾-tocopherol (5
days prior to the procedure and continued for a further 2 days
after procedure) in combination with 0.9% saline (1mL/kg/h
for 12 hours before and 12 hours after) was shown to be
effective in protecting against AKI. AKI occurred in 14.9%
of cases in the placebo group, but only in 4.9% and 5.9%
in the 𝛼- and 𝛾-tocopherol groups, respectively, suggesting
a protective effect of vitamin E against the nephrotoxicity of
iodinate contrast media.
Mesna (mercapto-ethane-sulfonate Na) is an agent with
antioxidant properties that has been shown to reduce
free radicals and restore reduced glutathione levels after
ischemic renal failure, thereby protecting the kidneys against
ischemia/reperfusion-induced oxidative damage [157]. Lud-
wig et al. [158] examined, in a randomized controlled trial,
the efficacy of sodium 2-mercaptoethanesulfonate (MESNA),
a reactive oxygen scavenger, in at-risk patients given radio-
graphic contrast agents. The i.v. administration of 1600mg
Mesna versus placebo, together with i.v. hydration with 0.9%
saline, resulted in the occurrence of AKI in 7 patients in the
placebo group and none in the Mesna group (𝑃 = 0.005).
Further studies would be necessary to confirm such a positive
outcome [1].
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5.7. Nebivolol. Nebivolol is a third-generation 𝛽
1
-adrenergic
receptor antagonist.
Toprak et al. [159] have hypothesized that Nebivolol
protects the kidney against contrast-induced AKI through
its antioxidant and NO-mediated vasodilating action. In
experimentalWistar-albino rats they observed that Nebivolol
induced a significant increase of CrCl reduced by diatrizoate,
a decrease of medullary congestion, protein casts and tubular
necrosis, systemic and renal oxidative stress, microprotein-
uria caused by the contrast medium, and an increase of the
kidney nitrite level decreased by diatrizoate.
Gu¨nebakmaz et al. [160] enrolled 120 patients undergo-
ing coronary angiography and ventriculography, who were
hydrated with i.v. isotonic saline: group I received 600mg N-
acetylcysteine every 12 hours for 4 days, group II received
5mg nebivolol every 24 hours for 4 days, and group III
patients were only hydrated: 9 patients in group I (22.5%)
developed AKI, as did 8 patients (20.0%) in group II and
11 patients (27.5%) in group III (𝑃 = 0.72). However,
a statistically significant increase in SCr was observed at
day 5 compared with baseline levels only in group I (N-
acetylcysteine, from 1.42 to 1.52, 𝑃 = 0.02) and group III
(hydration only, from 1.43 to 1.55, 𝑃 = 0.01); the increase of
SCr (from 1.40 to 1.48, 𝑃 = 0.06) in group II (Nebivolol) did
not reach statistical significance.
5.8. Statins. Recent studies have shown a beneficial effect of
statins to prevent AKI in patients undergoing PCI [161–165].
Khanal et al. [162] studied 29409 patients who had both
baseline preprocedure andpeak postprocedure SCrmeasured
at the time of their PCI to compare patients who received
preprocedure statins with those who did not. Patients on
preprocedure statins had a lower incidence of AKI (4.37
versus 5.93, 𝑃 < 0.0001) and nephropathy requiring dialysis
(0.32 versus 0.49, 𝑃 < 0.03). They suggest initiating statin
therapy before percutaneous coronary interventions.
Patti et al. [163] prospectively studied 434 patients under-
going PCI, with a follow-up for 4 years. Statin-treated patients
(n. 260) had a significantly lower incidence of AKI (3% versus
27%, 𝑃 < 0.0001) versus untreated patients (number: 174)
and had better postprocedural CrCl (80 versus 65mL/min,
𝑃 < 0.0001); 4-year survival free of major adverse cardiac
events was highest in statin-treated patients without AKI.
Thus, the early protective effect of statins translates into better
long-term event-free survival.
Zhang et al. [164] performed ameta-analysis of published
randomized clinical trials (8 published clinical trials with
1423 patients) to evaluate whether short-term administration
of high-dose statin is superior to conventional-dose statin
or placebo in preventing contrast-induced AKI in patients
undergoing catheterization and interventional procedures.
They observed an effectiveness of short-term high-dose
statin pretreatment for both decreasing the level of SCr and
reducing the rate of AKI.
Current guidelines for coronary revascularization recom-
mend the use of high dose of statins before PCI to reduce
the risk of periprocedural myocardial infarction; but the
beneficial clinical effect of statin pretreatment in patients
undergoing coronary angioplasty arises not only from a car-
diac protection against periprocedural myocardial injury but
also from a renal protection against AKI caused by iodinated
contrast media [165]. Actually, statins exert multiple non-
lipid-lowering (pleiotropic) effects, such as improvement of
endothelial function and reduction of inflammatory and
immunomodulatory processes, of oxidative stress andplatelet
adhesion; they may contribute to both cardio- and nephro-
protection even in the short-term [165].
This is not surprising, considering that hypercholes-
terolemia has been suggested to be a predisposing factor to
ARF on the basis of a study in experimental ARF, character-
ized by compromised NO synthesis and enhanced ROS gen-
eration [166, 167]. But the nephroprotective effect of statins
has been attributed to its antioxidant, anti-inflammatory, and
antithrombotic properties and to its vasodilator property
mediated by NO, which improves renal microcirculation
[166, 168, 169].
Rosuvastatin (10mg/day for five days, two days before,
three days after the procedure) reduced the risk of AKI in
patients with diabetes mellitus and chronic kidney disease
undergoing coronary/peripheral arterial angiography [170].
Leoncini et al. [171] treated 252 patients with acute coro-
nary syndrome, who were scheduled for an early invasive
procedure and were at high risk for contrast-induced AKI,
with high doses of rosuvastatin, that is, 40mg on admission,
followed by 20mg/day.The incidence ofAKIwas significantly
lower in the statin group than in controls (6.7% versus
15.1%, 𝑃 = 0.003). Also simvastatin had a dose-dependent
nephroprotective effect in experimental rats treated with
radiocontrast agents [168]. Patients on pravastatin had an
even lower incidence of AKI than patients on simvastatin
[172, 173].
Acikel et al. [174] have demonstrated that short-term
atorvastatin (40mg/day 3 days before the procedure) and
chronic atorvastatin therapy had a protective effect on renal
function after coronary angiography.
Patti et al. [175] investigated whether short-term high-
dose atorvastatin load decreases the incidence of AKI after
PCI. Patients with acute coronary syndrome undergoing PCI
(𝑛 = 241) randomly received either atorvastatin (80mg 12
hours before intervention with another 40mg preprocedure
dose, 𝑛 = 120) or placebo (𝑛 = 121): 5% of patients in the
atorvastatin group developed AKI versus 13.2% of those in
the placebo group (𝑃 = 0.046). They conclude suggesting
early use of high-dose statins before percutaneous coronary
revascularization to protect patients against contrast media
nephrotoxicity.
5.9. Steroids. Ribichini et al. [176] have suggested a short
course of high-dose steroids as an effective preventive
measure against contrast-induced AKI: 38 patients under-
going cardiovascular procedures were given either pred-
nisone (1mg/kg of oral prednisone, 12–24 hours before
and 24 hours after the angiographic procedure) plus i.v.
saline plus hydration (1mL/kg/hour of 0.9% saline, 12 hours
before the procedure) or hydration alone. SCr was tested
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before and 24–48 hours after the procedure, while neu-
trophil gelatinase-associated lipocalin (NGAL), kidney injury
molecule-1 (KIM-1), protein, and albumin were assayed in
spot urine before and 6 hours after the procedure. NGAL
and KIM-1 tended to rise after the procedure to a lesser
degree in the prednisone group; proteinuria and albuminuria
decreased significantly in the prednisone group. The authors
concluded that short course of prednisone reduces the
procedure-induced changes in biomarkers of renal tubular
damage.
5.10. Diuretics. Since enhanced transport activity with oxy-
gen consumption plays an important causal role of renal
hypoxia and both furosemide and mannitol reduce transport
activity, it has been suggested to use furosemide or mannitol
to protect against contrast-induced AKI. Furthermore, an
increase in urine output, as it occurs with furosemide and
mannitol, will decrease the contact time of contrast mate-
rial with tubular epithelium, thereby reducing the epithe-
lial damage. Obviously, inducing a high urine output with
diuretics in the absence of adequate fluid replacement is
deleterious. Thus, the use of furosemide or mannitol should
be associated with saline infusion to prevent salt depletion.
Marenzi et al. [177] performed a prospective, randomized
trial involving patientswithCRF, defined as an eGFR less than
60mL/min/1.73m2, scheduled for coronary angiography
requiring the use of the nonionic, low-osmolality contrast
agent iomeprol. In their study they utilized, for prevention
of AKI, the combination of hydration plus furosemide, to
prevent both fluid overload in response to intravenous hydra-
tion and hypovolemia as a result of high-volume diuresis
induced by furosemide administration. This was obtained by
delivering intravenous fluid in an amount exactly matched
to the volume of urine produced by the patient under the
effect of furosemide and precisely weighed. The result was a
significantly lower incidence of AKI when compared to the
patients treated with only hydration.
Several studies, however, have demonstrated either no
effect in protecting against contrastmedia or even deleterious
effect of furosemide and mannitol on renal function.
Thus, Solomon et al. [178] prospectively studied 78
patients with SCr of 2.1mg/dL undergoing cardiac angiog-
raphy. Patients received either 0.45 percent saline alone for
12 hours before and 12 hours after angiography, or saline
plusmannitol, or saline plus furosemide.They concluded that
hydration with 0.45 percent saline provides better protection
against acute decreases in renal function induced by radio-
contrast agents than does hydrationwith saline plusmannitol
or furosemide.
Similar results were obtained by Weinstein et al. [179]
who concluded that furosemide may be deleterious in the
prevention of radiocontrast nephropathy.
Thus, diuretics should be avoided before contrast expo-
sure in high-risk patients who are susceptible to volume
depletion.
Kurnik et al. [180] performed a multicenter, prospective,
randomized, double-blind, and placebo-controlled trial to
evaluate the efficacy of i.v. atrial natriuretic peptide (anaritide,
ANP 4–28) to prevent contrast-induced AKI in patients with
SCr >1.8mg/dL or eGFR of ≤65mL/min. Their conclusion
was that the administration of i.v. ANP before and during
a radiocontrast study did not reduce the incidence of AKI
in patients with preexisting CRF, with or without diabetes
mellitus.
5.11. Calcium Channel Blockers. Calcium Channel Blockers
have been hypothesized to have protective effects against
contrast-induced AKI. The rationale is the following: Ca2+
overload is considered to be a key factor in AKI; the
increase in intracellular calcium provokes a vasoconstrictive
response in intrarenal circulation and would be an impor-
tant mediator of epithelial cell apoptosis and necrosis. The
Na+/Ca2+ exchanger system is one of the main pathways of
intracellular Ca2+ overload. Yang et al. [181] have demon-
strated that in rats the pretreatment with KB-R7943, an
inhibitor of theNa+/Ca2+ exchanger system, significantly and
dose-dependently suppresses the increase of SCr following
diatrizoate administration.
Thus, the use of Calcium Channel Blockers has been
suggested for prevention of contrast-induced AKI. But their
use has given controversial results, sometimes protective [182,
183] and sometimes with no benefit at all [178, 184].
5.12. Other Substances. Urinary adenosine is increased after
contrast medium administration. The administration of
adenosine receptor antagonists reduces the risk of devel-
opment of contrast-induced AKI in both diabetic and
nondiabetic patients [59]. Thus, it has been thought that
adenosine antagonists (theophylline, aminophylline) could
have protective effects against contrast media. But their use
has given controversial results. Some authors have observed
beneficial effects against AKI [185–188]; others have denied
any beneficial results [189, 190].
Dopamine and dopamine agonists (e.g., fenoldopam,
a selective dopamine-1 receptor agonist with vasodilatory
properties) have given controversial results in protecting
against CIN, some positive [191–193], others negative [146,
190, 194, 195]. On the basis of our present knowledge, it
is better to avoid them, considering their adverse effects
(arrhythmia with dopamine and systemic hypotension with
intravenous fenoldopam).
Plasma and urine levels of endothelin-1 are increased in
diabetes and after exposure to high doses of contrast media
suggesting a role of endothelin-1 in diabetic nephropathy and
in contrast-induced AKI [58]. However, endothelin Receptor
Blockers have been proven deleterious as a prophylactic tool
against contrast-induced AKI [196].
Prostaglandin E1 has given some positive protective
results on renal function following contrastmedium injection
in patients with preexisting renal impairment [197], whilst
L-arginine has shown no beneficial or even harmful effects
[198].
5.13. Haemodialysis or Haemofiltration. It has been suggested
to remove iodinated radiocontrast media by haemodialy-
sis or haemofiltration immediately after the radiographic
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procedure. However, the extracorporeal removal of contrast
agents did not decrease the incidence of AKI in high-risk
patients [199–202]. The ERBP does “not recommend using
prophylactic intermittent haemodialysis or haemofiltration
for the purpose of prevention of contrast-induced AKI” [115].
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